Oral Semaglutide 50 mg May be Effective Option for Obesity Treatment, According to OASIS 1 Study Authors
ADA 2023. Once-daily oral semaglutide 50 mg induced 15.1% weight loss in adults with overweight or obesity without type 2 diabetes vs placebo.
Oral GLP-1 Agonist Orforglipron Leads to ~15% Mean Body Weight Reduction in Adults with Overweight/Obesity
ADA 2023: The investigational oral GLP-1 RA resulted in weight loss comparable to injectable GLP-1 RA formulations and requires no food or water restrictions.
Survodutide, Novel Dual GLP-1/Glucagon Agonist, Achieves ~19% Weight Loss in People with Overweight, Obesity
ADA 2023: Among survodutide-treated participants in a phase 2 study, more than half lost more than 50% of baseline bodyweight, reported PI Carel le Roux, MBChB, PhD.
SURMOUNT-2: Tirzepatide Treatment Leads to Average 15% Weight Loss in Adults with T2D, Obesity
ADA 2023: SURMOUNT-2 findings show tirzepatide is associated with greater weight loss in adults with T2D than any other treatment studied to date.
Friday's 5 Quotes for Primary Care
SGLT-2 inhibitors show broad cardiometabolic efficacy; colchicine approved for CV inflammation, astronomical diabetes rates; plus 2 more quotes of note.
Global Diabetes Prevalence Will Double by 2050, Affecting 1.3 Billion People: New Predictions
Type 2 diabetes will continue to comprise more than 90% of this population and obesity will be the primary driver, according to Global Burden of Disease researchers.
“Triagonist” Therapy for Type 2 Diabetes and Comorbidities to be Previewed at 2023 ADA Scientific Sessions
ADA 2023. Retatrutide, an investigational triple GLP-1/GIP/glucagon agonist, may provide benefits in liver fibrosis and obesity as well as in glycemic control.
SGLT-2 Inhibitor HF, CV Benefit Found Consistent Across Populations with T2D, CKD, HF
SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.
Obesity & Type 2 Diabetes: Early Intervention Critical in Reducing Risk for Complications
Early intervention is important to reduce the risk for complications for patients with obesity and type 2 diabetes. Two obesity experts explain more, here.
Daily Dose: Healthy Lifestyle & Risk of CVD Among Postmenopausal Women With Normal BMI
Your daily dose of clinical news you may have missed.
For Unknown Causes of Kidney Disease, Genetic Testing Holds Promise
A recent American Kidney Fund survey of 300 primary care and specialty clinicians found ~15% of their patients had kidney disease of unknown origin.
Home Blood Pressure Monitoring among Older US Adults
Among adults aged 50 to 80 years with a BP-related condition, less than half say they regularly monitor BP at home; one-third are "not very concerned" about their BP.
Empagliflozin and Empagliflozin/Metformin Win FDA Approval for Pediatric Type 2 Diabetes
The 2 SGLT-2 inhibitor-based medications are the first in the class to be approved for pediatric T2D and provide a much needed additional oral treatment option for the population.
Daily Dose: Cardiovascular Safety of Testosterone-Replacement Therapy in Men with Hypogonadism
Healthy Lifestyle Linked to Primary CVD Prevention in Postmenopausal Women with Normal BMI
Higher scores on a healthy lifestyle index were associated with significantly reduced risk of incident CVD among women aged 50-79 years with BMI between 18.5 and 25.0.
USPSTF: Screen Adults for Depression, Anxiety, Suicide Risk in Primary Care
Primary care clinicians should screen all adults for the 3 mental health conditions to ensure timely referral for appropriate treatment.
FDA Approves Low-Dose Colchicine as First Anti-inflammatory Therapy to Reduce Cardiovascular Events
Colchicine 0.5 mg is associated with reduction in a wide range of CV events in patients already on statin therapy, supporting the long-held "anti-inflammatory" hypothesis.
Testosterone Replacement Does Not Increase Risk for CV Events in Men with Hypogonadism, New Study Finds
ENDO 2023. In older men with hypogonadism and CVD, there was no difference in incident CVD between those taking testosterone and those taking placebo.
Obesity and Type 2 Diabetes: Experts Analyze the Role of Insulin Resistance
Listen to 2 obesity experts discuss and analyze the role of insulin resistance in type 2 diabetes and obesity.
Daily Dose: PCOS Associated with Higher Mortality Risk
